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Abstract
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease leading to immunological aberrations and
excessive multiple autoantibody production. The aim of this study was to investigate the prevalence of multiple autoantibodies
in SLE patients utilizing the multiplex system method.
We analyzed the presence of elevated titers of anti-Ro, anti-La, anti-RNP, anti-Sm, anti-Jo1, anti-centromere, anti-Scl-70,
anti-histone, and anti-dsDNA antibodies in 199 serum samples (113 SLE patients, 86 healthy donors). We compared the
type, level and number of autoantibodies and the correlation between the autoantibody proﬁle and disease severity utilizing
the SLEDAI score.
Elevated titers of at least one autoantibody were detected in 48% of 42 SLE patients. Elevated titers of anti-Ro antibodies
were most commonly detected. The distribution of speciﬁc autoantibodies was: anti-Ro- 23.8%, anti-dsDNA- 19%, anti-
histone- 19%, anti-RNP- 14.2%, anti-La antibodies- 11.9%, anti-Sm- 7.1%, anti-Scl 70-4.7%, and anti-centromere- 2.4%.
Utilizing ROC analysis, the sensitivity and speciﬁcity of anti-DNA antibodies at a cutoff value of 34IU/ml were 87.1% and
79.4% respectively. Elevated titers of anti-Jo1 antibody were not detected. There was a correlation with the titer of anti-Ro
antibodies and disease activity by the SLEDAI score. Seven patients harbored one autoantibody only, 15 patients harbored 2–
3 autoantibodies, 3 patients harbored 4–5 autoantibodies, and one patient harbored 6 autoantibodies. A correlation between
the number of autoantibodies per patient and disease severity was found. One patient with a multitude of autoantibodies had
severe lupus and a myriad of clinical manifestations.
In conclusion, the multiplex system is speciﬁc and sensitive, provides an autoantibody proﬁle in a single test, and may be
useful as a diagnostic test for SLE. Elevated anti-Ro antibodies are associated with severe disease. An autoantibody load may
be indicative of more severe disease.
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Introduction
Systemic lupus erythematosus (SLE) is a multi-
system autoimmune disease with diverse clinical and
laboratory features. SLE patients may have mild
disease characterized by joint and cutaneous involve-
ment, moderate disease when there is serositis or
hematological involvement (thrombocytopenia, ane-
mia, leukopenia) or severe disease manifested by
injury to the renal tissue or central nervous system.
SLE is classically characterized by elevated titers of
antinuclear antibodies (ANA) and anti-dsDNA
antibodies. The autoantibody proﬁle may include a
response to other extractable nuclear antigens (ENA)
including Ro/SSA, La/SSB, RNP, and Sm. The
autoantibody proﬁle is usually established by the
ELISA method where the patient’s serum is tested for
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activity index (SLEDAI) is a clinical tool utilized to
establish active disease based on clinical and
laboratory ﬁndings in a recent period.
Flow-based, multiplex bead arrays (MBA) were
recently developed from a variety of applications
including the detection of ENA antibodies. This
platform offers the potential for a rapid and sensitive
method to assess multiple analytes in a single test.
AtheNA multi-lyte test system is a homogeneous,
multiplexed system for autoantibody analysis. It is a
precise and easy to use technology for simultaneous
quantative multi-autoantibody detection (Fulto et al.
1997). Polystyrene microparticles of uniform size are
used as the solid phase. Beads are dyed using a deﬁned
combination of two dyes. The dying process results in
100 distinct bead sets. The intensity of the two colors
identiﬁes each bead set. Unique bead sets can be
conjugated with various, unique target molecules of
interest. Thousands of each bead set are combined to
form a multiplex bead suspension. The bead suspen-
sion is added to the wells of a microplate. If the patient
possesses an antibody to more than one bead set, all
beads will be labeled with antibody and then the
conjugate. The bead suspension is analyzed using the
AtheNA Instrument.
Beads ﬂow through the ﬂow cell and light scatter
determine discrete events. One laser identiﬁes the
amount of reporter on the surface. The other
determines the amount of classiﬁcation dye or
identiﬁes the bead set. Antigens included in the
assay included: dsDNA, SSA/Ro, SSB/La, Sm, RNP,
histone, centromere, Scl-70, and Jo-1.
The purpose of this study was to evaluate the
AtheNA multi-lyte ANA system an MBA technology
for the detection of ANA and ENA antibodies in the
sera of SLE patients and healthy individuals.
Clinically, the number and type of autoantibodies
detected per patient was compared to the SLEDAI
score for the presence of active disease.
We have recently shown the speciﬁcity of the
multiplex system in Sjogren’s syndrome (Gilburd et al.
2004), rheumatoid arthritis, scleroderma, and SLE
(Shovman et al.). In this study, we chose to assess the
clinical importance of an autoantibody proﬁle in SLE
patients. We confronted the question: Does an
autoantibody proﬁle aid in predicting a pattern of
clinical manifestations and/or disease severity?
Patients and methods
Patients
Sera samples from 199 consecutive and unselected
individuals were tested utilizing the multiplex system.
The sera samples were obtained from 113 patients
with SLE and 86 healthy individuals obtained from
the National Blood Bank.
Deﬁnition of clinical features and disease activity of SLE
patients
All SLE patients fulﬁlled the ACR classiﬁcation
criteria for SLE (Tan et al. 1982). In 42 SLE patients,
we compared the type, level and number of
autoantibodies with clinical activity utilizing the
SLEDAI score (Bombardier et al. 1992).
The patients attended the Lupus Clinic at our
institution from 2000–2002. All patients underwent
a documented medical interview and physical
examination by a qualiﬁed rheumatologist. A serum
sample from each patient was collected and the
disease severity was assessed utilizing the SLEDAI
score.
Clinical and serological data were obtained from the
Lupus Clinic Database (Microsoft-Excel 2000).
Autoantibody determination
AtheNA Multi-Lyte ANA test System (Zeus Scien-
tiﬁc, Inc. Raritan, NJ, USA) was utilized for
simultaneous determination of autoantibodies to
nine different antigens (dsDNA, SSA/Ro, SSB/La,
Sm, RNP, Scl-70, Jo-1, centromere B, and histone).
The multiplex system is a diagnostic test which uses
reagents that contain a mixture of different micro-
sphere populations. Each of these populations are
characterized by a speciﬁc red ﬂuorescent color tone
and a detection reagent on the surface. When
incubated with a few microliters of a patient sample,
each microsphere population captures its speciﬁc
target molecule from the liquid phase. Analytes bound
to the surface of the microspheres can be labeled using
a green ﬂuorescent labeling reagent, thus enabling the
detection of many autoantibodies in one step.
Positive tests for all individual autoantibodies in
the AtheNA Multi-Lyte ANA test System were
deﬁned as values greater than 120units/ml (cutoff
normal range).
Statistical analysis
Statistical analysis was performed using the STAT
program. Descriptive statistics and linear correlation
were utilized to compare between the various assays.
Results
Autoantibody proﬁle
SLE sera. Elevated titers of at least one autoantibody
were found in 48% of SLE patients and elevated titers
of anti-Ro antibodies were most commonly detected.
The prevalence of speciﬁc autoantibodies was: anti-
Ro- 23.8%, anti-dsDNA-19%, anti-histone- 19%,
anti-RNP- 14.2%, anti-La antibodies- 11.9%, anti-
Sm- 7.1%, anti-Scl 70-4.7%, and anti-centromere-
2.4 (Table I). Utilizing ROC analysis, the sensitivity
G. Zandman-Goddard et al. 108and speciﬁcity of anti-DNA antibodies at a cutoff
value ¼ 34IU/ml were 87.1% and 79.4% respectively.
Elevated titers of anti-Jo1 antibody were not detected.
Seven patients harbored one autoantibody only, 15
patients harbored 2–3 autoantibodies, 3 patients
harbored 4–5 autoantibodies, and one patient
harbored 6 autoantibodies.
Normal sera. The sera of 86 healthy individuals were
tested by the AtheNA system. Elevated titers of anti-
nuclear antibodies were detected in 3 (3%) sera from
healthy subjects. None of the sera had anti-SS/A, anti-
SS/B, anti-Jo-1, anti-dsDNA, anti-centromere or anti-
histone activity. Anti-Sm, anti-RNP and anti-Scl-70
were detected each in one (1%) serum (not shown).
Autoantibody proﬁle and clinical activity
The autoantibody proﬁle and clinical activity were
evaluated in 42 SLE patients. Patients with an
autoantibody load had more severe disease (Table II).
Table III shows the distribution of autoantibodies in
26 SLE patients with elevated titers of at least one
autoantibody.
A correlation was detected between the titer of anti-
Ro antibodies and SLEDAI (Table IV). Patients with
very high titers of anti-Ro antibodies also had more
severe disease. We searched for the coupling of certain
autoantibodies that may be found in elevated titers
together. Four of ﬁve patients harbored both elevated
titers of anti-Sm and anti-RNP antibodies. Elevated
titers of anti-Ro and anti-La antibodies were found in
8 of 17 patients. The coupling of elevated titers of
anti-RNP and anti-Sm antibodies was found in 4 of 6
patients. The number of autoantibodies in a single
patient was not associated with speciﬁc manifestations
of disease (nephritis, central nervous system involve-
ment) but was associated with an elevated SLEDAI
score.
The patient with 6 different elevated autoanti-
bodies and a high SLEDAI score is a 56 year old
woman, married with 4 children, of a Yemenite
descent. SLE was diagnosed 25 years ago, after her
third delivery. Clinical manifestations of the disease
include Jaccoud’s arthropathy, discoid lupus, photo-
sensitivity, livedo reticularis, digital ulcer, alopecia,
pleural effusion, deep vein thrombosis, mild pancy-
topenia, sensorimotor poyneuropathy, low C3, C4,
and elevated titers of anti-cardiolipin antibodies.
Discussion
More than 100 autoantibodies are reported in the
sera of SLE patients (Sherer et al. 2004). Some of
those autoantibodies are pathogenic, have a role in
the diagnosis of the disease and are utilized in the
assessment of disease activity (Cervera and Shoe-
nfeld). Although anti-dsDNA antibodies are the gold
standard for SLE, some patients do not harbor
elevated titers of anti-dsDNA antibodies and hence
ENA detection is important. In our analysis of 9
autoantibodies by the multiplex system, elevated
titers of at least one autoantibody were found in 48%
of patients. Seven patients harbored one autoanti-
body only, 15 patients harbored 2–3 autoantibodies,
3 patients harbored 4–5 autoantibodies, and one
patient harbored 6 autoantibodies. A correlation
between the number of autoantibodies per patient
and disease severity was found. The value of the
presence of multiple autoantibodies in a single patient
is not well established. One may suggest that the
presence of many autoantibodies in a single patient
could be associated with more severe disease. We
found an association between the number of
autoantibodies and the SLEDAI score. However, by
utilizing the SLEDAI score alone, we were unable to
detect a pattern of autantibodies associated with
major organ involvement. Perhaps, clinical assess-
ment at the onset of disease could be more
informative.
The multiplex bead array system has recently been
utilized for autoantibody detection in various
autoimmune diseases (Martins et al. 2004). Thus,
in our previous study, we compared the speciﬁcity
and sensitivity of the recognition of ANA and 9
autoantibodies by the AtheNA system to the
established ELISA method. Screening of samples
obtained from healthy donors for ANA by AtheNA
technology demonstrated a high concordance rate of
99% with the conventional ELISA test. Screening of
disease related samples (systemic sclerosis, rheuma-
Table I. Prevalence of the ENA proﬁle utilizing the multiplex
system*.
Autoantibody SLE sera (n-42) % Literature* %
SSA 23.8 21.4
SSB 11.9 7.1
Sm 7.1 10.7
RNP 14.2 32.1
Histone 19.0 ND
Scl-70 4.7 0
Centromere 2.4 ND
Jo-1 0.0 ND
*Martins et al. (2004).
Table II. Comparison of the presence of autoantibodies to the
SLEDAI score in SLE patients.
Number of patients Number of AB
Mean SLEDAI score
(range)
22 1–3 5.1 (0–10)
34 – 5 8
16 2 1
AtheNA immunoassay for SLE 109toid arthritis) for ANA by technology also conﬁrmed
a high rate of concordance with the traditional
ELISA (Shovman et al.). In another study, we
assessed the multiplex system in 37 patients with
Sjogren’s syndrome. It was found to be sensitive and
speciﬁc: Anti-Ro and anti-La antibodies were
detected in 84% and 74% respectively, as described
in the literature, while other autoantibodies were not
found (Gilburd et al. 2004). In our current study,
many autoantibodies were detected in patients
indicating the diverse immune dysregulation in
lupus as opposed to the prevalence of one single
characteristic autoantibody encountered in organ
speciﬁc autoimmune diseases such as Sjogren’s
syndrome. Interestingly, we found elevated titers of
anti-Ro antibodies in 23.8% of patients that
correlated with disease activity. Very elevated titers
of anti-Ro antibodies may be useful in the
assessment of disease activity especially in patients
that do not present with elevated titers of anti-
dsDNA autoantibodies.
In another recent study, with a multiplexed
ﬂuorescent microsphere immunoassay, reactivity to
ﬁve of the most diagnostically useful ENA was
measured in 249 serum samples, including samples
from 56 patients previously documented to have SLE
(Martins et al. 2004). Signiﬁcant concentrations of 5
autoantibodies measured by the multiplexed assay in
56 SLE patients were similar to ours, except for RNP,
where we had a lower frequency (Table I).
Routinely, autoantibodies speciﬁc for other auto-
immune diseases, including anti-Jo1 antibodies for
polymyositis, and anti-centromere and anti-Scl-70
antibodies for systemic sclerosis are not evaluated in
SLE patients. Some studies imply a relation of these
autoantibodies to clinical manifestations or disease
activity in lupus patients (Al Attia and D’Souza 2003,
Gussin et al. 2001). The importance of elevated titers
of anti-Scl 70 and anti-centromere antibodies in SLE
patients without overt clinical manifestations of
another coexistent autoimmune disease is not
Table III. Comparison of autoantibody proﬁle to the SLEDAI score in 26 SLE patients.
SAMPLE SSA SSB Sm RNP Scl 70 dsDNA Cent B Histone Nephritis CNS SLEDAI
1 þþ þ 22 11
2 þþ þ 224
3 þþ 222
4 þþ 220
5 þ 22 13
6 þþ þ þ þ 2 8
7 þþ 22 10
8 þ 2 þ 10
9 þþ 220
10 þþ 220
11 þ 22 10
12 þþþ þ þ þ 2 þ 21
13 þþ 2 7
14 þþ þ þ þ 226
15 þ 229
16 þþ 225
17 þþ þ 228
18 þ 224
19 þþ 222
20 þ þ 220
21 þþ 2 þ 12
22 þþ 222
23 þþ þ þ þ 2 11
24 þþ þ 2 5
25 þ 22 10
26 þþ þ 2 11
Table IV. Anti-Ro antibody level correlates with SLEDAI score.
Sample SLEDAI score Anti-Ro leve units/ml
20 0 121
9 0 142
4 0 252
10 0 1362
24 1 205
3 2 132
19 2 258
16 5 1416
15 9 1087
8 10 224
11 10 262
25 10 699
7 10 1585
26 11 304
1 11 398
5 13 1323
12 21 1727
cut-off normal range , 120 units/ml.
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an ensuing overlap syndrome.
Anti-Sm antibodies are rarely found without anti-
RNP because both proteins associate with common
snRNA species in the spliceosome. Anti-La is rarely
detected without anti-Ro because both associate
with a common type of RNA termed hYRNA
(Egner 2000).
No autoantibody activity was detected in the
majority of sera from normal individuals. This is in
accordance to ANA that is normally found in 3–5% of
the normal population and not indicative of ensuing
autoimmune disease. Natural autoantibodies exist in
low-medium titers, are of the IgM type, and hence
bind with low afﬁnity and avidity.
Considerable data conﬁrms the advantage of the
multiplexed technology and its applications in diverse
ﬁelds of medicine including cancer research, cytokines,
endocrinologic diseases, gene expression, genetic dis-
eases, and infectious diseases (Feng et al. 2004,
Rouquetteetal.2003.KeijandSteinkamp1998,Earley
etal.2002,Dunbar2003,Yeet al.2001,Martins2002,
Pickering et al. 2002, 2002, de Jager 2003, Brailey and
Susskind2003,Chestertonetal.2003,Pretletal.2003,
Seideman and Peritt 2002). Our data suggests that the
sensitivity and the precise technology of the AtheNA
system makes it a feasible simultaneous detection of
quantative multiple autoantibodies in a single micro
titer, in the sera of SLE patients.
In conclusion, the multiplex system is speciﬁc and
sensitive, provides an autoantibody proﬁle in a single
test, and may be useful as a diagnostic test for SLE.
Clinical evaluation revealed that elevated anti-Ro
antibodies are associated with severe disease and an
autoantibody load may be indicative of more severe
disease.
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